Google requests settlement with Russia's antimonopoly watchdog — regulatorBusiness & Economy February 28, 15:25
Russian top diplomat says humanitarian situation in Mosul much worse than in AleppoRussian Politics & Diplomacy February 28, 15:23
Putin says Russia will not support sanctions against Syrian leadershipRussian Politics & Diplomacy February 28, 15:10
Putin says he may close down Kant base if Kyrgyzstan no longer needs Russian helpMilitary & Defense February 28, 14:51
Russian Defense Ministry denies plans for setting up new military bases abroadMilitary & Defense February 28, 14:31
Russia is ready to discuss START-III Treaty revision with USRussian Politics & Diplomacy February 28, 14:30
Russia, Turkey in talks over supply of air defense systemsMilitary & Defense February 28, 14:26
Kremlin envoy calls for ban on keeping wild animals as house petsSociety & Culture February 28, 13:42
Erdogan says Turkish troops set to ‘liberate’ Syria’s RaqqaWorld February 28, 13:37
MOSCOW, September 28 (Itar-Tass) — A unique Russian project for the development of nano-scale systems for targeted delivery of hormonal and anti-ulcer medicines will be presented at the 4th international innovation forum opening in St Petersburg on Wednesday, Orest Ibragimov, one of project managers and general director of the Izvarino Pharma Company, has told Itar-Tass.
Only five laboratories in the world engage in such development efforts. "The project is part of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period until 2020," Ibragimov pointed out.
The market share of domestic innovative medicinal preparations is less than two percent. In view of this, one of the Strategy priorities is to stimulate the development and production of domestic innovations, the formation of scientific research centers and clusters to develop innovative medicinal preparations. As a result, the localization of the production of generics must mount up to 50 percent while 50 percent of innovative preparations must serve as substitutes for imported ones. The overall budget of the project is 550 million roubles.
The entire research and production blocks will be located in the territory of the Russian Federation -- in the Republic of Tatarstan in the grounds of Khimgrad technopolis.
"The essence of our technology is in developing nano-scale particles with pre-set properties based on biodegradable biopolymers. This implies an innovative approach and development of the full cycle of production -- from the creation of a substance to a ready-made medicinal form," Ibragimov said.
The outcome of the implementation of the project will be that the development of nano-scale systems for the delivery of medicinal preparations will ensure an improvement by a factor of ten and more in the bioaccessibility of highly active effective substances. This was not achieved by previous development efforts.
The new compound will have a greater bioaccessibility and a lesser cost. The project will be environmentally safe. Work is organized up to GMP standards, and equipment will be fully isolated, ruling out contact of the personnel with highly-active effective substances; an air purifying system will ensure complete filtration of the outlet air. The complex is expected to be brought up to full capacity in the first quarter of 2012.
Within the next ten years, the State envisages the financing of a Federal purpose-oriented programme for the development of the pharmaceutical medical industry in an amount of 188,000 million roubles, with 122,500 million roubles out of the amount being resultant of Federal budget resources.
The main role of the programme is to help reduce the gap between documentarian and research work and direct production and commercialization on the market. According to estimates by Minister of Industry and Trade Viktor Khristenko, by 2015, ninety percent of strategic, vitally important preparations must be produced directly by domestic companies.